First-lineBiguanideMetabolic specialist

9amHealth Reviews Metformin

The default first rung and a core part of the bundle, which includes generic medications and labs in a single predictable PMPM.

Sold as Glucophage · Reviewed September 19, 2026

7.3Adequate

9amHealth

Full evaluation

Vendor PMPM

$34–$72

Metformin at list

Generic and inexpensive — typically a rounding error against any GLP-1

What “First-line” means here

Prescribed as a first-line option. No lower-cost trial is required before a member can start.

The pairing

How 9amHealth handles Metformin

These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.

Full 9amHealth evaluation All Metformin vendors

Access status: First-line
Gating: Offered first to nearly all eligible members.
Prescribes directly: Yes
Step therapy: Yes
Prior authorization: Yes
Titration protocol: Generic-first protocol with documented escalation criteria to branded GLP-1s
Off-ramp: Pharmacist-led deprescribing review at defined intervals
Care team: Physicians, Nurse practitioners, Registered dietitians, Pharmacists

Ask 9amHealth this

Model the bundle against our current PBM generic pricing. For some buyers the bundle is a premium rather than a saving.

Watch out

Model the bundle against your existing PBM generic pricing. For some buyers the bundle is a premium, not a saving.

The molecule

Metformin in one page

Not a GLP-1, and not a weight-loss drug — but the first rung of nearly every credible step-therapy protocol, and effectively free. How a vendor uses metformin tells you whether its cost discipline is real.

Clinical profile

Drug class: Biguanide
Brand names: Glucophage — Type 2 diabetes
Mechanism: Reduces hepatic glucose production and improves insulin sensitivity. Weight effect is modest and secondary to the glycemic effect.
Administration: Oral, daily, usually with an extended-release formulation to improve tolerability.
Titration: Gradual escalation over several weeks, primarily to manage gastrointestinal tolerability.
Typical result: Modest weight reduction — typically low single digits as a percentage — alongside meaningful glycemic improvement in appropriate patients.
Generic available: Yes

Known side effects

Gastrointestinal effects, substantially reduced by extended-release formulations
Long-term B12 depletion warranting periodic monitoring
Lactic acidosis, rare and largely confined to renal impairment

What benefits teams need to know

A useful test of vendor honesty

Every vendor lists metformin. Far fewer can show you what share of their population is maintained on it without escalating. Ask for that number — it separates vendors with a step-therapy protocol from vendors with a step-therapy slide.

It does not compete with GLP-1s on weight

Metformin is not an alternative to incretin therapy for a member who needs substantial reduction. Its role is identifying the members who never needed the expensive drug, not substituting for it in those who do.

Alternatives

Other vendors and Metformin

Same molecule, materially different access rules. The status column is where the cost difference lives.

All Metformin vendors

Other vendors covering Metformin
Vendor	Access	Score	PMPM
Virta Health Metabolic specialist	First-line	8.7	$40–$95
Form Health Full-service clinical	Adjunct	8.0	$58–$105
Twin Health Metabolic specialist	First-line	7.8	$55–$120
Found Full-service clinical	First-line	7.6	$45–$85
Vida Health Full-service clinical	First-line	7.5	$38–$78
Teladoc Health Navigation & orchestration	First-line	7.4	$18–$44

Same vendor

9amHealth across the formulary

How this vendor positions each molecule tells you more about its cost discipline than any single review does.